<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-816
Date of Submission: 2024-11-30

This report was submitted by a Patient from Horn and Sons Medical Center concerning patient ANON-PX-9723. The subject is a 24-year-old other with a significant medical history including asthma, anxiety, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Subcutaneous route at a dosage of 105mg, initiated on 2024-11-14 for Thromboembolism prevention and discontinued on 2024-11-26; Levothyroxine (Thyroid hormone) administered via the Intravenous route at a dosage of 356mg, initiated on 2024-11-14 for Hypothyroidism and discontinued on 2024-11-26.

On approximately 2024-11-17, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Angioedema, Maculopapular Rash. The Nausea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Angioedema was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Maculopapular Rash was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed interest and advised knowledge. The current patient status regarding this symptom is 'Fatal'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. 

</data>
report_id: ADR-2024-816
report_date: '2024-11-30'
patient_details:
  patient_id: ANON-PX-9723
  gender: Other
  relevant_history:
  - asthma
  - anxiety
  - chronic kidney disease
  age_at_reaction: 24
suspected_drugs:
- drug_name: Warfarin
  dosage: 105mg
  route_of_administration: Subcutaneous
  start_date: '2024-11-14'
  indication_for_use: Thromboembolism prevention
  drug_class: Anticoagulant
  end_date: '2024-11-26'
- drug_name: Levothyroxine
  dosage: 356mg
  route_of_administration: Intravenous
  start_date: '2024-11-14'
  indication_for_use: Hypothyroidism
  drug_class: Thyroid hormone
  end_date: '2024-11-26'
adverse_reactions:
- symptom_name: Nausea
  onset_date: '2024-11-17'
  severity: Mild
  outcome: Not Recovered
  intervention_required: false
- symptom_name: Angioedema
  onset_date: '2024-11-17'
  severity: Mild
  outcome: Fatal
  intervention_required: false
- symptom_name: Maculopapular Rash
  onset_date: '2024-11-17'
  severity: Mild
  outcome: Fatal
  intervention_required: true
  intervention_details: Prescribed interest and advised knowledge.
causality_assessment:
  assessment_conclusion: Possible
  dechallenge_rechallenge: Not applicable
  naranjo_score: 2
reporting_facility: Horn and Sons Medical Center
reporter_type: Patient
